Abstract
Background Repetitive transcranial magnetic stimulation (rTMS) has shown efficacy for treating depression, but not for all patients. Accurate treatment response prediction could lower treatment burden. Research suggests machine learning trained with electroencephalographic (EEG) data may predict response, but only a limited range of measures have been tested.
Objectives We used >7000 time-series features to comprehensively test whether rTMS treatment response could be predicted in a discovery dataset and an independent dataset.
Methods Baseline EEG from 188 patients with depression treated with rTMS (125 responders) were decomposed into the top five principal components (PCs). The hctsa toolbox was used to extract 7304 time-series features from each participant and PC. A classification algorithm was trained to predict responders from the feature matrix separately for each PC. The classifier was applied to an independent dataset (N = 58) to test generalizability on an unseen sample.
Results Within the discovery dataset, the third PC (which showed a posterior-maximum and prominent alpha power) showed above-chance classification accuracy (68%, pFDR = 0.005, normalised positive predictive value = 114%). Other PCs did not outperform chance. The model generalized to the independent dataset with above-chance balanced accuracy (60%, p = 0.046, normalised positive predictive value = 114%). Analysis of feature-clusters suggested responders showed more high frequency power relative to total power, and a more negative skew in the distribution of their time-series values.
Conclusion The dynamical properties of PC3 predicted treatment response with moderate accuracy, which generalized to an independent dataset. Results suggest treatment stratification from pre-treatment EEG may be possible, potentially enabling better outcomes than ‘one-size-fits-all’ treatment approaches.
Competing Interest Statement
In the last 3 years PBF has received equipment for research from Neurosoft, Nexstim and Brainsway Ltd. He has served on scientific advisory boards for Magstim and LivaNova and received speaker fees from Otsuka. He has also acted as a founder and board member for TMS Clinics Australia and Resonance Therapeutics. MA holds equity/stock in neurocare and Sama Therapeutics, serves as consultant to Synaeda, Sama therapeutics and Roche; Brainclinics Foundation received equipment support from neuroconn and Deymed. The other authors declare that they have no conflicts of interest.
Funding Statement
The research comprising the current study did not receive any direct funding. PBF is supported by a National Health and Medical Research Council of Australia Investigator grant (1193596).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used a subset of the full publicly available TDBRAIN dataset that contained participants over 18 years of age (N = 968). All participants received the EEG as part of their routine care and provided informed consent for their data to be recorded and shared for the purposes of research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Information: PBF is supported by a National Health and Medical Research Council of Australia Investigator grant (1193596).
Conflict of Interest: In the last 3 years PBF has received equipment for research from Neurosoft, Nexstim and Brainsway Ltd. He has served on scientific advisory boards for Magstim and LivaNova and received speaker fees from Otsuka. He has also acted as a founder and board member for TMS Clinics Australia and Resonance Therapeutics. MA holds equity/stock in neurocare and Sama Therapeutics, serves as consultant to Synaeda, Sama therapeutics and Roche; Brainclinics Foundation received equipment support from neuroconn and Deymed. The other authors declare that they have no conflicts of interest.
Data Availability
The TDBRAIN database and code are available on the Brainclinics Foundation website at www.brainclinics.com/resources and on Synapse at www.synapse.org/TDBRAIN.
